Annovis Bio (ANVS) Share-based Compensation (2019 - 2026)
Annovis Bio (ANVS) posted Share-based Compensation of $182823.0 for Q1 2026, down 48.72% sequentially from $356524.0 in Q4 2025, and down 63.43% YoY from $499887.0 in Q1 2025.
Annovis Bio (ANVS) Share-based Compensation (2019 - 2026) Analysis & Trends
Annovis Bio has reported Share-based Compensation for 8 years, with the latest figure at $182823.0 in Q1 2026.
- Quarterly Share-based Compensation fell 63.43% year-over-year to $182823.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 62.72% YoY) and the FY2025 annual result came in at $1.8 million, down 53.15% from the prior year.
- Share-based Compensation eased to $182823.0 in Q1 2026 per ANVS's latest filing, from $356524.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.4 million in Q1 2022 and troughed at $182823.0 in Q1 2026.
- A 5-year average of $1.2 million and a median of $882384.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 23720.83% in 2022, then slumped 76.35% in 2024.
- Over 5 years, Share-based Compensation stood at $1.5 million in 2022, then slumped by 39.47% to $882384.0 in 2023, then surged by 68.0% to $1.5 million in 2024, then sank by 75.95% to $356524.0 in 2025, then tumbled by 48.72% to $182823.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $182823.0, $356524.0, and $444647.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 182,823.00 |
| Mar 31, 2026 | 182,823.00 |
| Dec 31, 2025 | 356,524.00 |
| Dec 31, 2025 | 356,524.00 |
| Sep 30, 2025 | 444,647.00 |
| Sep 30, 2025 | 444,647.00 |
| Jun 30, 2025 | 496,618.00 |
| Jun 30, 2025 | 496,618.00 |
| Mar 31, 2025 | 499,887.00 |
| Mar 31, 2025 | 499,887.00 |
| Dec 31, 2024 | 1.48 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 393,080.00 |
| Sep 30, 2024 | 393,080.00 |
| Jun 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 364,765.00 |
| Mar 31, 2024 | 364,765.00 |
| Dec 31, 2023 | 882,384.00 |
| Dec 31, 2023 | 882,384.00 |